Ferring and Blackstone jointly invest in a new bladder cancer therapy
Category: #health  By Pankaj Singh  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ferring and Blackstone jointly invest in a new  bladder cancer therapy

Private investment firm, Blackstone Life Sciences and Ferring Pharmaceuticals recently announced joint investment of more than USD 570 million in a novel investigational  gene therapy, rAd-IFN/Syn3 (nadofaragene firadenovec). The therapy is being developed for the treatment of patients with high-grade BCG (Bacillus Calmette-Guérin) unresponsive and NMIBC (non-muscle invasive bladder cancer).

Ferring has created a new gene therapy company and Ferring subsidiary, FerGene to potentially commercialize rAd-IFN/Syn3 in the U.S. and to advance the global clinical development. FerGene’s aim is to acquaint patient population with this promising therapy. Ferring will invest up to USD 170 million and Blackstone will invest USD 400 million in FerGene. Ferring is also expected to potentially launch & commercialize rAd-IFN/Syn3 outside of the U.S.

Currently in late Phase 3 development, rAd-IFN/Syn3 has been granted Breakthrough Therapy designation and had its Biologics License Application  accepted for filing and granted Priority Review by the Food and Drug Administration.

Frederik Paulsen, Chairman of Ferring Pharmaceuticals, was reportedly quoted saying that it requires dedicated focus and capabilities to bring a novel gene therapy to the market. FerGene, will aid Ferring Pharmaceuticals with the resources & team needed to potentially bring rAd-IFN/Syn3 to patients.

Paulsen added that through this new joint financing model between Blackstone Life Sciences and Ferring, the company aims to ensure that more and more people with high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer may benefit from this novel gene therapy, if it is approved.

Phase 3 clinical trial results for nadofaragene firadenovec will be presented at the SUO (Society of Urologic Oncology) 20th Annual Meet in Washington, DC. FerGene will hold the marketing authorization of nadofaragene firadenovec, upon the potential FDA approval.

Dr. Stephen A. Boorjian, Professor of Urology at Mayo Clinic in Rochester and the Coordinating Investigator for the trial was reported to state that this trial expands the potential for search of effective alternatives to cystectomy for patients with high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer, which can significantly improve patient care in future.
 

Source Credit: https://www.blackstone.com/media/press-releases/article/ferring-and-blackstone-life-sciences-invest-over-$570-million-usd-in-novel-gene-therapy-for-bladder-cancer-patients



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...